20:44 , Aug 3, 2018 |  BioCentury  |  Finance

Lin’s new chapters

Taiwanese biotech Lin Bioscience Inc. and its wholly owned San Diego subsidiary Lin Bioscience Co. Ltd. are planning sequential listings in Taiwan and the U.S. to fund clinical programs targeting different markets. Lin has two...
16:03 , Apr 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Patient sample, cell culture and mouse studies suggest inhibiting CDC25A, CDC25B and CDC25C could help treat breast cancer. In breast cancer patients, high tumor levels of CDC25A, CDC25B and CDC25C correlated with...
04:15 , Apr 13, 2018 |  BC Innovations  |  Targets & Mechanisms

Hello RNA

BioCentury’s analysis of new and emerging targets presented at this year’s AACR meeting reveals a surge in activity in non-coding RNAs, as researchers continue to expand target space. The results also reflect the ongoing high...
15:49 , Mar 28, 2018 |  BC Innovations  |  Distillery Techniques

Biomarkers

TECHNOLOGY: Gene profiling; SNPs; tissue markers Tumor expression levels of any one of 32 genes could predict survival in estrogen receptor-positive breast cancer. The protocol uses Capture Hi-C -- a method that maps transcriptional start...
02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
21:44 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Cancer Research UK begins Phase I of Lilly's CDC7 inihibitor in solid tumors

Cancer Research UK (London, U.K.) began a Phase I trial of LY3143921 to treat advanced solid tumors, including bowel, lung, ovarian, urothelial, pancreatic, breast, head and neck, and esophageal tumors in about 68 patients. The...
01:05 , Apr 21, 2017 |  BC Innovations  |  Product R&D

Making marks at AACR

Biomarkers that could stratify patients, point to treatment combinations or predict toxicity were a major part of the conversation at this year’s AACR conference, where they emerged as potential difference makers for a range of...
19:12 , Mar 24, 2017 |  BC Week In Review  |  Company News

Columbia University, Memorial Sloan Kettering, Lin BioScience deal

The university and Memorial Sloan granted Lin BioScience exclusive, worldwide rights to LBS-007 and related IP. Lin said the small molecule that inhibits cell division cycle 7-related protein kinase (CDC7) has shown preclinical effectiveness against...
23:08 , Jan 3, 2017 |  BC Innovations  |  Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy A method of inhibiting N. meningitidis Cas9 with proteins from N. meningitidis could be used to control CRISPR gene editing in human cells. The method involved using any one of three Cas9-binding,...
08:00 , Dec 14, 2015 |  BioCentury  |  Product Development

Following CoMMpass

Amidst a flood of promising data for hot targets, indications and technologies at this year's American Society of Hematology meeting, one collection of presentations stands out not only for the wide-reaching implications of their data,...